Wellesley Pharma, a leading pharmaceutical brand, is dedicated to improving the lives of millions of individuals suffering from nocturia. Their flagship product, Nocturol, is designed to effectively reduce and even eliminate nocturia symptoms. Backed by 10 US method-of-use patents, Nocturol has gained global recognition for its ability to minimize bathroom visits.

The brand is actively pursuing patent protection worldwide, with granted patents in various countries including Australia, New Zealand, Russia, Singapore, South Africa, and Taiwan. Wellesley Pharma also has a groundbreaking patent pending for a lower dosage version of Nocturol, specifically developed to assist children who struggle with bedwetting. With an estimated 3.

2 million bedwetting children in the United States alone, Nocturol offers an effective and safe solution, as elevated prostaglandin levels are often the underlying cause for both nocturia and bedwetting. By providing targeted relief and enhancing the overall quality of life, Wellesley Pharma aims to bring relief to those afflicted by these conditions. For more information on Wellesley Pharmaceuticals or Nocturol, please reach out via the provided contact details